Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vitrafy Life SciencesASX:VFY -0.71%5 3-Year RORE % is 0.00 as of Dec. 2025. GuruFocus rates ASX:VFY with a GF Score™ of 5/100. The stock has 5 warning signs investors should review. Among 2,546 Software companies, Vitrafy Life Sciences ranks worse than 39277.26% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Vitrafy Life Sciences's 3-Year RORE % for the quarter that ended in Dec. 2025 was 0.00%.
The industry rank for Vitrafy Life Sciences's 3-Year RORE % or its related term are showing as below:
ASX:VFY's 3-Year RORE % is not ranked *
in the Software industry.
Industry Median: 2.99 * Ranked among companies with meaningful 3-Year RORE % only.
Vitrafy Life Sciences (ASX:VFY) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Vitrafy Life Sciences 3-Year RORE % Related Terms
Vitrafy Life Sciences 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Vitrafy Life Sciences's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:VFY vs MSFT, ORCL, PLTR: 3-Year RORE % Comparison
For the Software - Infrastructure subindustry, Vitrafy Life Sciences's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitrafy Life Sciences 3-Year RORE % vs Software Industry
For the Software industry and Technology sector, Vitrafy Life Sciences's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Vitrafy Life Sciences's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.
Vitrafy Life Sciences (ASX:VFY) has a 3-Year RORE % of 0.00 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Vitrafy Life Sciences and its competitors. According to the industry distribution chart, Vitrafy Life Sciences ranks #999999 out of 2546 companies in the Software industry.
Is Vitrafy Life Sciences' 3-Year RORE % too high?
Vitrafy Life Sciences' current 3-Year RORE % is 0.00. Based on the distribution chart, Vitrafy Life Sciences ranks #999999 out of 2546 companies in the Software industry, which is in the bottom quartile relative to peers. Overall, Vitrafy Life Sciences has a GF Score™ of 5/100, reflecting its overall financial health beyond just this single metric.
How does Vitrafy Life Sciences' 3-Year RORE % compare to MSFT and ORCL?
According to the Software industry distribution chart, Vitrafy Life Sciences ranks #999999 out of 2546 companies for 3-Year RORE %. This places Vitrafy Life Sciences in the lower half of its industry. The industry median 3-Year RORE % is 2.99. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Software company?
The median 3-Year RORE % among Software companies is 2.99, based on 2,546 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Vitrafy Life Sciences and its competitors. For the Software industry, the median 3-Year RORE % is 2.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vitrafy Life Sciences's current 3-Year RORE % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitrafy Life Sciences stock overvalued right now?
Vitrafy Life Sciences (ASX:VFY) has a current 3-Year RORE % of 0.00. The current 3-Year RORE % is 0.00. Vitrafy Life Sciences' overall GF Score™ is 5/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Vitrafy Life Sciences (ASX:VFY), the current 3-Year RORE % is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vitrafy Life Sciences Ltd developed a range of proprietary smart cryopreservation hardware devices and Lifechain, an integrated, cloud-based software platform, to provide a complete, vertically integrated cryopreservation solution to retain the quality of cryopreserved biomaterials. The company devices includes Vitrafy's Smart Cryopreservation Device; Vitrafy's Smart Thawing Device and Vitrafy's Smart Packaging.
5GF Score
Get the complete analysis for ASX:VFY
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VFY has been successfully added to your 
